

further detected the mechanisms of garlic's inhibitory effects on cell transformation. Both NIH3T3 cells and garlic treated human oral carcinoma cells were cultured in the 5% CO<sub>2</sub> incubator at 37°C. NIH3T3 cells were treated first with various concentrations of garlic extracts and followed by the chemical carcinogen DMBA. All of the cells were then extracted for purified DNA, and, thin-layer chromatography was performed for DNA-adduct analysis. The alterations of DNA-adduct in NIH3T3 cells, carcinoma cells, and garlic treated cells were clearly recognized. It indicates that the mechanism of chemopreventive efficacy of garlic on cell transformation might be related to DNA stereochemistry.

#### P47

##### Cancer prevention by selenium

K. Schumacher

*Hematological Oncological Practice, Gerlingen, Germany*

In 1993 the results of the nutrition intervention trial performed in Linxian were published (J Natl Cancer Inst 85: 141-149). The observation of 29,584 randomly assigned participants who were supported with micronutrients over 5 years resulted in a significant reduction of cancers in the selenium,  $\beta$ -carotin, and  $\alpha$ -tocopherol group. In the Clark study (JAMA 1996;276:1957-63) a total of 1312 patients with skin tumors were randomized on 200  $\mu$ g of yeast selenium or placebo for 4.5 yr of treatment and 6.5 yr of observation. Total cancer mortality was 50% less in the selenium vs placebo group (p 0.002). Relative to the placebo group the selenium group had 37% less total cancers, 63% less prostate cancer, 64% less colorectal cancer, and 46% less lung cancer. As far as the mechanism of tumor prevention by selenium is concerned there are several mechanisms under discussion. Selenium as part of the selenium-dependent enzymes like GSHPx protects cells against the DNA damage caused by reactive oxygen species. Further effects of selenium are the activation of DNA repair, modulation of cell division, thereby inhibiting rapid cell growth, and the development of mutations and mistakes of DNA replication. A recently published paper by Seo et al. (PANAS 2002;99:14548-53) indicates that maintenance of genomic stability by p53 can be separated from its growth suppressor or pro-apoptotic functions and may involve direct activation of DNA repair machinery. This is achieved by p53 interaction with a selenium containing compound. Seo et al. found that incubation with selenomethionine (SeMet) results in an unusual activation of p53 in cultured cells: a reduction of two specific cysteine residues within p53 leads to a conformational shift and induction of p53 DNA binding activity. This procedure requires a cellular protein Ref 1, a known redox factor that interacts with p53. Thus p53 becomes capable of activating DNA repair without affecting cell growth. Hence, p53 can contribute to genomic stability not only by eliminating damaged cells, but also through directly activating a DNA repair system, converting from a killer to a healer (Gudkov Nature Med 2002;8:1196-98).

#### P48

##### Progesterone receptor antagonists an alternative for breast cancer prevention

J. Hoffmann, R.B. Lichtner, U. Fuhrmann, H. Hess-Stumpp, G. Siemeister, A. Cleve, G. Neef, K. Parczyk, M.R. Schneider, K. Bosslet

*Schering AG, Corporate Research, Experimental Oncology, Berlin, Germany*

The biological activity of progesterone is mediated by the progesterone receptor (PR), which induces a cascade of transcriptional events, critical for maintenance and development of female reproductive organs. Blocking PR function by using a PR-antagonist allows the modulation of various endocrine processes which also might be responsible for gynecological or oncological diseases. It is well known that progesterone, in physiological concentrations participate in the proliferation of mammary carcinomas. Therefore it is obvious that antiprogestins can block the growth of breast tumors functionally expressing the PR. We describe the pharmacological characterization of a novel, highly potent PR-antagonist, that has a considerable potential for therapeutic intervention in breast cancer. The PR-antagonist showed high antiprogestagenic activity in vitro on both PR isoforms PR-A and PR-B. This high antiprogestagenic activity could also be demonstrated in several in vivo models. Subsequent experiments with breast cancer models showed a strong antiproliferative activity. In the nitroso-methylurea (NMU) and dimethyl-benzanthracene (DMBA)-induced mammary tumor models in the rat, treatment with the PR-antagonist completely suppressed the growth of established tumors and prevented the development of breast tumors when given prophylactically. Induction of tumor cell apoptosis was also found in our studies. The ability of these compounds to induce tumor cell differentiation that leads to apoptosis is unique among all other endocrine therapeutics. Our results revealed that the biological response to a progesterone antagonist does not seem to be only the result of competition of progesterone but rather may be accompanied by additional mechanisms. With these pharmacological properties a PR-antagonist may be a promising new option for clinical breast cancer therapy.

#### P49

##### Novel marine compounds - antitumor or genotoxic: Role of endpoint biomarkers

J. Arif<sup>1</sup>, M. Kunhi<sup>1</sup>, Y. Siddiqui<sup>1</sup>, K. El-Sayed<sup>2</sup>, K. Orabi<sup>3</sup>, A. Al-Hazzani<sup>1</sup>, M. Al-Ahdal<sup>1</sup>, F. Al-Khodairy<sup>1</sup>

<sup>1</sup>King Faisal Specialist Hospital and Research Center, Biological and Medical Research, Riyadh, Saudi Arabia;

<sup>2</sup>University of Louisiana at Monroe, Department of Basic Pharmaceutical Sciences, Monroe, Louisiana, Usa; <sup>3</sup>Kuwait University, Department of Pharmaceutical Chemistry, Safat, Kuwait

In the past two decades, thousands of novel marine compounds and their derivatives have been reported with diverse biological activities ranging from antiviral to antitumor. However, till date not a single anticancer drug was commercially developed. Based on the preliminary anticancer activities, many

marine compounds (didemnin B, jaspamide, girolline) made it to the human phase I and II clinical trials but due to their extreme toxicity they were later withdrawn. Most of these compounds were tested in vitro by high-throughput cost-effective screening assays (cytotoxicity, apoptosis and/or antiproliferation) for their anticancer potential exclusively using human or rodent cancer cell lines. DNA adducts have been widely used as biomarker of choice to determine the anticancer and/or genotoxic potentials of natural compounds, but none of the studies with marine compounds have used this biological marker. In the present study, we screened two of the novel marine compounds, manzamine A and sarcophine with antitumor activity, using benzo[a]pyrene (BP)-derived DNA adduct formation in MCF-7 cells as endpoint biomarker. Briefly, MCF-7 cells were treated with the compounds for 24 h followed by treatment with BP (0.5  $\mu$ M). Cells were harvested after 24 h incubation and DNA was isolated and analyzed for BP-derived DNA adducts by <sup>32</sup>P-postlabeling technique. Manzamine A (50  $\mu$ M) increased the BP-DNA adducts by 200% while sar-

cophine was ineffective. In contrast, at a higher dose (100  $\mu$ M), sarcophine substantially (400%) induced the formation of BP-DNA adducts; manzamine A was relatively ineffective at high concentration. However, at lower concentration (10  $\mu$ M), both compounds were ineffective. Further, manzamine A (50  $\mu$ M) substantially down-regulated the expression of p53, p21 and p16 while sarcophine (50  $\mu$ M) induced the level of p21 but was ineffective against p16 and p53. Manzamine A (50  $\mu$ M) almost completely inhibited the residual DNA repair ability in MCF-7 cells as measured by host cell reactivation while sarcophine was ineffective. Based on our preliminary results, these compounds may be classified as potentially genotoxic since they have the ability to enhance the carcinogen-DNA adduct formation due to modulation of phase I/II and/or DNA repair enzymes. This is the first ever observation using DNA adducts as endpoint biomarker with the marine compounds which stresses the importance of biomarkers in determining the anticancer potential of compounds.